EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study

Astrid Lipplaa iD, Willem H Schreuder, Sarina E C Pichardo, Hans Gelderblom iD

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad196 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2023. Verfasst von Astrid Lipplaa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Bone Neoplasms, Giant Cell Tumor of Bone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since giant cell tumors of bone (GCTB) and other giant cell rich tumors of bone (GCRTB) share the histological presence of osteoclastic giant cells and expression of RANK/RANKL, we hypothesized that GCRTB will respond similarly to denosumab as GCTB. The primary objective of this study was to determine the efficacy of denosumab in patients with GCRTB that have recurred or require morbid surgery.

Methods

In this open-label, multicenter, phase II trial, patients with GCRTB were included (June 2018-March 2020). Recruitment was stopped because of low accrual. Patients received denosumab (120 mg) subcutaneously (SC) on day 1 of every 4-week cycle with a loading dose of 120 mg SC on days 8 and 15.

Results

Three patients were enrolled. One withdrew consent before start of study. The remaining patients had central giant cell granuloma of the jawbone (CGCG). Median treatment duration was 15 cycles (range 12-18). In both subjects, improvement in ossification of lesions was seen. Median follow-up was 28.5 months (range 20-37). One patient developed a recurrence for which surgery was performed.

Conclusion

Due to critical emerging real-world data of denosumab in GCRTBs, the study was prematurely stopped and not supportive of use of denosumab for this indication. (ClinicalTrials.gov Identifier: NCT03605199).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsBone NeoplasmsGiant Cell Tumor of BoneHumansDenosumabGiant Cells

Stichwörter der Autor:innen

aneurysmal bone cystdenosumabgiant cell granulomagiant cell rich tumor of bonesystemic therapy

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Oral and Maxillofacial Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
  • Academic Center for Dentistry, University of Amsterdam, Amsterdam, The Netherlands.
  • Head and Neck Surgery and Oncology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Oral and Maxillofacial Surgery, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Astrid Lipplaa, Hans Gelderblom

Förderung

  • Amgen

Zitieren

APA

Lipplaa, A., Schreuder, W. H., Pichardo, S. E. C., & Gelderblom, H. (2023). Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study. The Oncologist. https://doi.org/10.1093/oncolo/oyad196

Vancouver

Lipplaa A, Schreuder WH, Pichardo SEC, Gelderblom H. Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study. The Oncologist. 2023. doi:10.1093/oncolo/oyad196

BibTeX
@article{Lipplaa2023,
  author = {Lipplaa, Astrid and Schreuder, Willem H and Pichardo, Sarina E C and Gelderblom, Hans},
  title = {Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad196}
}
Kostenlos starten →